CoChat
Sign Up
Cited by 25

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Up-regulated expression of CD86 on circulating intermediate monocytes correlated with disease severity in psoriasis

Nguyen, Chuyen Thi Hong, Kambe, Naotomo, Yamazaki, Fumikazu, Ueda-Hayakawa, Ikuko, Kishimoto, Izumi, Okamoto, Hiroyuki·2018·Journal of Dermatological Science
DOI 10.1016/j.jdermsci.2018.01.005
Open this paper in CoChat — free account

Abstract

Background The number of intermediate monocytes (CD14 ++ CD16 + ) increases in many inflammatory conditions. However, it is not yet known which functional markers expressed by these populations are linked to the pathogenesis of psoriasis. Objectives We evaluated the expression of functional markers on circulating intermediate monocytes. Our goal was to correlate specific populations and their markers with the clinical severity of psoriasis. Methods A cohort of 43 psoriatic patients was subjected to analysis. The proportion of intermediate monocytes with CD86 expression was evaluated by flow cytometry. Serum beta defensin-2 levels were measured by ELISA. Immunofluorescent staining was performed in order to identify the presence of CD14 + CD16 + cells that co-expressed CD86 in affected skin tissues. Results Upregulated expression of CD86 on the intermediate subset (but not the number of intermediate monocytes) correlated with clinical severity as measured by PASI scores and serum beta defensin-2 levels. Immunostaining also showed the presence of CD86 + CD14 + CD16 + cells in the epidermis and dermis of psoriatic plaques, which was associated with increased epidermal proliferation. Conclusion These results suggest that the expression of CD86 on circulating intermediate monocytes could be used as an index in clinical practice and provide novel insights into how these cells join a complex immune network under the pathological conditions of psoriasis.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jdermsci.2018.01.005

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 26

  1. Zawada, 2011, SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset, Blood, 118, e50, 10.1182/blood-2011-01-326827 · DOI
  2. Wong, 2011, Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets, Blood, 118, e16, 10.1182/blood-2010-12-326355 · DOI
  3. Belge, 2002, The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF, J. Immunol., 168, 3536, 10.4049/jimmunol.168.7.3536 · DOI
  4. Frankenberger, 1996, Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis, Blood, 87, 373, 10.1182/blood.V87.1.373.373 · DOI
  5. Wong, 2012, The three human monocyte subsets: implications for health and disease, Immunol. Res., 53, 41, 10.1007/s12026-012-8297-3 · DOI
  6. Golden, 2015, Chronic psoriatic skin inflammation leads to increased monocyte adhesion and aggregation, J. Immunol., 195, 2006, 10.4049/jimmunol.1402307 · DOI
  7. Fujisawa, 2012, Adsorptive depletion of CD14(+)CD16(+) proinflammatory monocyte phenotype in patients with generalized pustular psoriasis: clinical efficacy and effects on cytokines, Ther. Apher. Dial., 16, 436, 10.1111/j.1744-9987.2012.01108.x · DOI
  8. Yamanaka, 2014, Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils, J. Dermatol., 41, 679, 10.1111/1346-8138.12560 · DOI
  9. Augustin, 2017, Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries, J. Eur. Acad. Dermatol. Venereol., 31, 1316, 10.1111/jdv.14286 · DOI
  10. Imhof, 2004, Adhesion mechanisms regulating the migration of monocytes, Nat. Rev. Immunol., 4, 432, 10.1038/nri1375 · DOI
  11. Pai, 2006, Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women, Atherosclerosis, 186, 132, 10.1016/j.atherosclerosis.2005.06.041 · DOI
  12. Rogacev, 2011, CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease, Eur. Heart J., 32, 84, 10.1093/eurheartj/ehq371 · DOI
  13. Tonel, 2010, Cutting edge: a critical functional role for IL-23 in psoriasis, J. Immunol., 185, 5688, 10.4049/jimmunol.1001538 · DOI
  14. Mitra, 1995, Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression, J. Immunol., 154, 2668, 10.4049/jimmunol.154.6.2668 · DOI
  15. Johansen, 2016, Characterization of TNF-alpha- and IL-17A-mediated synergistic induction of DEFB4 gene expression in human keratinocytes through IkappaBzeta, J. Invest. Dermatol., 136, 1608, 10.1016/j.jid.2016.04.012 · DOI
  16. Kolbinger, 2017, beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis, J. Allergy Clin. Immunol., 139, 923, 10.1016/j.jaci.2016.06.038 · DOI
  17. Rohrl, 2010, Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2, J. Immunol., 184, 6688, 10.4049/jimmunol.0903984 · DOI
  18. Jansen, 2009, Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin, PLoS One, 4, e4725, 10.1371/journal.pone.0004725 · DOI
  19. Perera, 2012, Psoriasis, Annu. Rev. Pathol., 7, 385, 10.1146/annurev-pathol-011811-132448 · DOI
  20. Finet, 2016, Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors, J. Eur. Acad. Dermatol. Venereol., 30, 1742, 10.1111/jdv.13674 · DOI
  21. Madanagobalane, 2012, The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India, Australas. J. Dermatol., 53, 190, 10.1111/j.1440-0960.2012.00905.x · DOI
  22. de Matos, 2016, The effect of insulin resistance and exercise on the percentage of CD16(+) monocyte subset in obese individuals, Cell Biochem. Funct., 34, 209, 10.1002/cbf.3178 · DOI
  23. Roberts, 2015, The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic, Aliment. Pharmacol. Ther., 41, 293, 10.1111/apt.13042 · DOI
  24. Jin, 2017, Serum human beta-defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients, Dermatology, 233, 164, 10.1159/000475809 · DOI
  25. Bracke, 2014, Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies, Exp. Dermatol., 23, 199, 10.1111/exd.12321 · DOI
  26. Erkin, 2007, Effect of PUVA, narrow-band UVB and cyclosporin on inflammatory cells of the psoriatic plaque, J. Cutan. Pathol., 34, 213, 10.1111/j.1600-0560.2006.00591.x · DOI · Paper page

Cited by

Sorted by citations

See all 25

Metadata

Authors
Nguyen, C. T. H., Kambe, N., Yamazaki, F., Ueda-Hayakawa, I., Kishimoto, I., & Okamoto, H.
Venue
Journal of Dermatological Science
Publisher
Elsevier BV
Published
2018-05
Volume
90
Issue
2
Pages
135-143
ISSN
0923-1811
DOI
10.1016/j.jdermsci.2018.01.005
Cited by
25
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review